Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill.

Large pharmaceutical conglomerate Eli Lilly has announced plans to build a $6 billion manufacturing facility in Huntsville, Alabama. The site will focus on the production of small molecules and ...

Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs. Wall Street may be pricing in too ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...